

Attn: Trading and Market Making/Legal and Compliance/Operations/Systems UNIFORM PRACTICE ADVISORY (UPC #27-23) 7/24/2023 Clovis Oncology, Inc. (CLVSQ)

Notice has been received that the above Company's Joint Chapter 11 Plan of Liquidation became effective on 7/11/2023. Pursuant to the plan, Interests shall be extinguished, cancelled, and released on the Effective Date. Each holder of an Allowed Unsecured Note Claim shall receive in full satisfaction, settlement, and release of, and in exchange for such Allowed Unsecured Note Claim its Pro Rata Share of the GUC CVRs. Please consult the company's Joint Chapter 11 Plan of Liquidation for further details.¹

Issuer	Security Description	CUSIP	Rate of Interests per \$1,000 Notes
Clovis Oncology Inc	1.25% Senior Unsecured Notes due 2025	189464AC4	1,007.67289
Clovis Oncology Inc	4.5% Senior Unsecured Notes due 2024	189464AE0	1,016.27757
Clovis Oncology Inc	4.5% Senior Unsecured Notes due 2024	189464AG5	1,016.27757

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Market Operations- 1-866-7760800.

¹ See e.g., In re: Clovis Oncology, Inc., et al Debtors Chapter 11 Case No. 22-11292 (JKS) (Jointly Administered) Joint Chapter 11 Plan of Liquidation for Clovis Oncology, Inc and Its Affiliated Debtors.